The IMID Forum

Prof Bijlsma presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2020.

A preview of the latest research at EULAR 2020. Prof Bijlsma presents a preview of the upcoming EULAR 2020 congress, highlighting important abstracts in cytokine signalling.

Prof Iain McInnes discusses PsA & Hep B. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.

The global effort improving patient outcomes amid COVID-19. Prof Peter Nash discusses the global rheumatology register for COVID-19 with Prof Philip Robinson.

Prof Iain McInnes discusses vasculitis and zoster. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Kevin Winthrop from Oregon Health & Science University. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition Prof Kevin Winthrop discusses the long-term effectiveness of the live zoster vaccine.

The global effort improving patient outcomes amid COVID-19. Past President of EULAR Prof Johannes Bijlsma discusses global rheumatology registries for COVID-19 with EULAR registry group member Prof Kimme Hyrich.

COVID-19 guidance for rheumatologists. Prof Peter Nash discusses the challenges COVID-19 poses with infections specialist Prof Kevin Winthrop.

First to identify destructive properties of IL-17 and received the prestigious Carol Nachman prize in 2010 for his contribution. In this podcast, Prof Pierre Miossec discusses the pathophysiology of RA alongside Prof Tsutomu Takeuchi from Keio University. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, the...

Timo Gaber and Paula Hoff from Charité Berlin. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, the impact of tofacitinib on the bone healing process is discussed.

Prof Schett from University of Erlangen-Nuremberg. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Prof Schett discusses how JAK inhibitors can increase bone formation by stimulating osteoblasts.

Prof Iain McInnes discusses bone homeostasis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Muirhead Professor of Medicine, President of EULAR, and Sir James Black Prize Medal winner. In this podcast, Prof Iain McInnes discusses the inception of JAK inhibitors during his time at the National Institutes of Health with Prof Peter Nash from the University of Queensland. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the fiel...

Dr Giovanni Orsolini from the University of Verona. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Giovanni Orsolini discusses the potential of JAK inhibitors to halt bone erosion, independent of their effects on inflammation.

Prof Iain McInnes discusses JAK selectivity. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Head of the Division of Rheumatology at Karolinska Institute and a co-author of more than 100 articles in peer review journals. In this podcast, Prof Anca Catrina discusses the role of antibodies in the pathogenesis of RA with Prof Johannes Bijlsma from University Medical Centre, Utrecht. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts...

Prof Vibeke Strand from Stanford University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Vibeke Strand discusses improvements in patient-reported outcomes with upadacitinib.

Iain McInnes discusses patient-reported outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Member of the US Centers for Disease Control and a co-author of more than 100 publications. In this podcast, Prof Kevin Winthrop discusses the impact concomitant treatments have on HZ risk with Professor Maurizio Cutolo from the University of Genova. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their cu...

Professor McInnes presents the most notable papers of 2019. You can find detailed summaries of the papers highlighted on http://www.cytokinesignalling.com/en/publications/review-article/511/

Professor McInnes presents the monthly podcast reviewing a paper by Professor Ying‐Chou Chen and another paper by Professor Genovese.

Professor McInnes presents the monthly podcast reviewing a paper by Dr Katie Bechman and another paper by Professor Lee YH.

In this edition of Congress Author Podcasts, recorded at ACR 2019, the latest data from the FINCH studies are presented by Professors Taylor, Westhovens and Winthrop, in addition to filgotinib safety data from a phase 2 Psoriatic Arthritis trial, presented by Professor Coates.

In this edition, recorded at ACR 2019, real-world tofacitinib safety data is presented by Professor Kremer and the impact of baricitinib and tofacitinib on pain is analysed by Professors Taylor and Dougados

In this edition experts, including Professor Smolen and Professor McInnes, present the latest data for the recently approved JAK inhibitor, upadacitinib. The presentations include: data from the SELECT trials, safety analyses, switching from TNF inhibitors, and the mode of action of upadacitinib.